Last reviewed · How we verify
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
B-cell non-Hodgkin's lymphoma (B-NHL) is the most common type of NHL. Although novel immunotherapies represented by anti-CD20 monoclonal antibodies and CAR-T cell therapies have significantly improved the prognosis of B-NHL patients, there are still nearly one-third of patients who are resistant to initial treatment or relapse after remission. R-CHOP combined with novel drugs was expected to improve the prognosis. Therefore, this study aimed to investigate the potential of Orelabrutinib combined with Rituximab and chemotherapy.
Details
| Lead sponsor | Shandong Provincial Hospital |
|---|---|
| Phase | PHASE3 |
| Status | UNKNOWN |
| Enrolment | 130 |
| Start date | Thu Apr 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Diffuse Large B-cell Lymphoma
- Mantle Cell Lymphoma
- B-cell NonHodgkin Lymphoma
Interventions
- Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
Countries
China